ARROWHEAD PHARMACEUTICALS, INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that ARROWHEAD PHARMACEUTICALS, INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $11.26M | Dec 11, 2018 |
| FY2018 | Jun 30, 2018 | $727.4K | Dec 11, 2018 |
| FY2018 | Mar 31, 2018 | $650.1K | Dec 11, 2018 |
| FY2018 | Dec 31, 2017 | $3.51M | Dec 11, 2018 |
| FY2018 | Sep 30, 2017 | $8.71M | Dec 11, 2018 |
| FY2018 | Jun 30, 2017 | $9.34M | Dec 11, 2018 |
| FY2018 | Mar 31, 2017 | $8.99M | Dec 11, 2018 |
| FY2018 | Dec 31, 2016 | $4.37M | Dec 11, 2018 |
| FY2017 | Sep 30, 2016 | $31.3K | Dec 12, 2017 |
| FY2017 | Jun 30, 2016 | $39.6K | Dec 12, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $829.45M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $3.55M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $240.74M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $243.23M | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $138.29M | Nov 29, 2023 |
| FY2020 | Sep 30, 2020 | $7.63M | Nov 23, 2020 |
| FY2020 | Jun 30, 2020 | $27.38M | Nov 23, 2020 |
| FY2020 | Mar 31, 2020 | $23.53M | Nov 23, 2020 |
| FY2020 | Dec 31, 2019 | $29.45M | Nov 23, 2020 |
| FY2020 | Sep 30, 2019 | $43.29M | Nov 23, 2020 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($1.63M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($599.49M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($205.28M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | ($176.06M) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | ($140.85M) | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | ($84.55M) | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $67.98M | Nov 22, 2021 |
| FY2020 | Sep 30, 2018 | ($54.45M) | Nov 23, 2020 |
| FY2017 | Sep 30, 2017 | ($10.73M) | Dec 12, 2017 |
| FY2017 | Jun 30, 2017 | ($5.52M) | Dec 12, 2017 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $98.35M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($601.08M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($205.00M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | ($178.51M) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | ($149.04M) | Nov 29, 2023 |
| FY2020 | Sep 30, 2020 | ($50.12M) | Nov 23, 2020 |
| FY2020 | Jun 30, 2020 | ($15.95M) | Nov 23, 2020 |
| FY2020 | Mar 31, 2020 | ($22.24M) | Nov 23, 2020 |
| FY2020 | Dec 31, 2019 | ($4.85M) | Nov 23, 2020 |
| FY2020 | Sep 30, 2019 | $9.64M | Nov 23, 2020 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $607.16M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $505.87M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $353.19M | Nov 25, 2025 |
| FY2015 | Sep 30, 2015 | $47.27M | Dec 14, 2015 |
| FY2015 | Sep 30, 2014 | $23.14M | Dec 14, 2015 |
| FY2015 | Sep 30, 2013 | $8.71M | Dec 14, 2015 |
| FY2014 | Sep 30, 2012 | $5.39M | Nov 25, 2014 |
| FY2012 | Sep 30, 2011 | $3.28M | Dec 28, 2012 |
| FY2011 | Sep 30, 2010 | $529.6K | Dec 20, 2011 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $179.55M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($462.85M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | ($153.89M) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | ($136.13M) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $171.31M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | ($95.80M) | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $173.04M | Nov 22, 2021 |
| FY2020 | Sep 30, 2018 | ($47.22M) | Nov 23, 2020 |
| FY2019 | Sep 30, 2017 | ($23.94M) | Nov 25, 2019 |
| FY2018 | Sep 30, 2016 | ($64.43M) | Dec 11, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $22.67M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $141.47M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $176.74M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $52.78M | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | $23.57M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $11.95M | Nov 28, 2022 |
| FY2021 | Sep 30, 2019 | $12.00M | Nov 22, 2021 |
| FY2020 | Sep 30, 2018 | $1.42M | Nov 23, 2020 |
| FY2019 | Sep 30, 2017 | $7.92M | Nov 25, 2019 |
| FY2018 | Sep 30, 2016 | $3.86M | Dec 11, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $1.39B | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $1.14B | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $765.55M | Nov 26, 2024 |
| FY2023 | Sep 30, 2022 | $691.94M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $710.15M | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | $522.50M | Nov 22, 2021 |
| FY2020 | Sep 30, 2019 | $349.85M | Nov 23, 2020 |
| FY2019 | Sep 30, 2018 | $111.61M | Nov 25, 2019 |
| FY2018 | Sep 30, 2017 | $104.02M | Dec 11, 2018 |
| FY2017 | Sep 30, 2016 | $128.18M | Dec 12, 2017 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $466.05M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $185.44M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | $271.34M | Nov 26, 2024 |
| FY2023 | Sep 30, 2022 | $398.52M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $408.82M | Nov 28, 2022 |
| FY2020 | Sep 30, 2020 | $461.78M | Nov 23, 2020 |
| FY2020 | Sep 30, 2019 | $244.59M | Nov 23, 2020 |
| FY2019 | Sep 30, 2018 | $95.80M | Nov 25, 2019 |
| FY2018 | Sep 30, 2017 | $81.42M | Dec 11, 2018 |
| FY2017 | Sep 30, 2016 | $95.58M | Dec 12, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($1.63B) | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($1.63B) | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | ($1.03B) | Nov 26, 2024 |
| FY2023 | Sep 30, 2022 | ($820.76M) | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | ($644.69M) | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | ($503.84M) | Nov 22, 2021 |
| FY2020 | Sep 30, 2019 | ($419.29M) | Nov 23, 2020 |
| FY2019 | Sep 30, 2018 | ($487.27M) | Nov 25, 2019 |
| FY2018 | Sep 30, 2017 | ($432.82M) | Dec 11, 2018 |
| FY2017 | Sep 30, 2016 | ($398.44M) | Dec 12, 2017 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Sep 30, 2021 | $184.43M | Nov 22, 2021 |
| FY2021 | Sep 30, 2020 | $143.58M | Nov 22, 2021 |
| FY2020 | Sep 30, 2019 | $221.80M | Nov 23, 2020 |
| FY2019 | Sep 30, 2018 | $30.13M | Nov 25, 2019 |
| FY2018 | Sep 30, 2017 | $24.84M | Dec 11, 2018 |
| FY2018 | Sep 30, 2016 | $85.37M | Dec 11, 2018 |
| FY2018 | Sep 30, 2015 | $81.21M | Dec 11, 2018 |
| FY2017 | Sep 30, 2014 | $132.51M | Dec 12, 2017 |
| FY2016 | Sep 30, 2013 | $19.11M | Dec 14, 2016 |
| FY2015 | Sep 30, 2012 | $3.38M | Dec 14, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | (5) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | (1) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | (1) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | (1) | Nov 29, 2023 |
| FY2020 | Sep 30, 2020 | 0 | Nov 23, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Nov 23, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Nov 23, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Nov 23, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 23, 2020 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | (5) | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | (1) | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | (1) | Nov 26, 2024 |
| FY2023 | Sep 30, 2021 | (1) | Nov 29, 2023 |
| FY2020 | Sep 30, 2020 | 0 | Nov 23, 2020 |
| FY2020 | Jun 30, 2020 | 0 | Nov 23, 2020 |
| FY2020 | Mar 31, 2020 | 0 | Nov 23, 2020 |
| FY2020 | Dec 31, 2019 | 0 | Nov 23, 2020 |
| FY2020 | Sep 30, 2019 | 0 | Nov 23, 2020 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 135.70M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 124.38M | Nov 25, 2025 |
| FY2024 | Sep 30, 2023 | 107.31M | Nov 26, 2024 |
| FY2023 | Sep 30, 2022 | 105.96M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | 104.33M | Nov 28, 2022 |
| FY2021 | Sep 30, 2020 | 102.38M | Nov 22, 2021 |
| FY2020 | Sep 30, 2019 | 95.51M | Nov 23, 2020 |
| FY2019 | Sep 30, 2018 | 88.51M | Nov 25, 2019 |
| FY2018 | Sep 30, 2017 | 74.79M | Dec 11, 2018 |
| FY2017 | Sep 30, 2016 | 69.75M | Dec 12, 2017 |